- Home
- PLTR vs NVO Comparison
PLTR vs NVO Comparison
Compare PLTR & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLTR
- NVO
- Stock Information
- Founded
- PLTR 2003
- NVO 1923
- Country
- PLTR United States
- NVO Denmark
- Employees
- PLTR N/A
- NVO N/A
- Industry
- PLTR Retail: Computer Software & Peripheral Equipment
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLTR Technology
- NVO Health Care
- Exchange
- PLTR Nasdaq
- NVO Nasdaq
- Market Cap
- PLTR 283.0B
- NVO 278.0B
- IPO Year
- PLTR 2020
- NVO N/A
- Fundamental
- Price
- PLTR $137.30
- NVO $73.79
- Analyst Decision
- PLTR Hold
- NVO Buy
- Analyst Count
- PLTR 20
- NVO 3
- Target Price
- PLTR $90.78
- NVO $112.00
- AVG Volume (30 Days)
- PLTR 86.0M
- NVO 8.9M
- Earning Date
- PLTR 08-04-2025
- NVO 08-06-2025
- Dividend Yield
- PLTR N/A
- NVO 2.18%
- EPS Growth
- PLTR 92.54
- NVO 17.93
- EPS
- PLTR 0.23
- NVO 3.40
- Revenue
- PLTR $3,115,024,000.00
- NVO $43,922,211,349.00
- Revenue This Year
- PLTR $38.79
- NVO $18.59
- Revenue Next Year
- PLTR $28.59
- NVO $15.61
- P/E Ratio
- PLTR $594.54
- NVO $21.75
- Revenue Growth
- PLTR 33.45
- NVO 24.11
- 52 Week Low
- PLTR $21.23
- NVO $57.00
- 52 Week High
- PLTR $144.86
- NVO $148.15
- Technical
- Relative Strength Index (RSI)
- PLTR 59.78
- NVO 52.32
- Support Level
- PLTR $136.08
- NVO $70.58
- Resistance Level
- PLTR $144.86
- NVO $81.44
- Average True Range (ATR)
- PLTR 6.11
- NVO 1.66
- MACD
- PLTR 0.09
- NVO -0.27
- Stochastic Oscillator
- PLTR 70.84
- NVO 29.51
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.